Aileron Therapeutics IncNASDAQ:ALRN
- LAST PRICE5.0000
- TODAY'S CHANGE (%)0.0700 (1.4199%)
- Bid / Lots4.3500/ 1
- Ask / Lots5.1600/ 1
- Open / Previous Close5.2400 / 4.9300
- Day Range
- 52 Week Range
- Volume80,550
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ALRN |
|---|---|---|
| 09:32 ET | 4249 | 5.24 |
| 09:34 ET | 1500 | 4.8358 |
| 09:45 ET | 4425 | 5.4 |
| 09:48 ET | 300 | 5.43 |
| 09:50 ET | 100 | 5.205 |
| 09:54 ET | 2600 | 5.1999 |
| 09:56 ET | 250 | 5.1425 |
| 10:21 ET | 100 | 5.08 |
| 10:26 ET | 1726 | 5 |
| 10:28 ET | 100 | 5 |
| 10:30 ET | 500 | 4.98 |
| 10:33 ET | 250 | 4.94 |
| 10:39 ET | 100 | 5 |
| 11:11 ET | 100 | 5.1 |
| 11:13 ET | 100 | 5.075 |
| 11:15 ET | 200 | 5.03 |
| 11:18 ET | 100 | 5.01 |
| 11:20 ET | 100 | 5.04 |
| 11:31 ET | 400 | 5 |
| 11:33 ET | 1622 | 5 |
| 11:36 ET | 600 | 4.98 |
| 11:38 ET | 1170 | 4.99 |
| 11:44 ET | 100 | 5 |
| 11:51 ET | 100 | 5.075 |
| 12:16 ET | 3400 | 5.01 |
| 12:18 ET | 400 | 5.01 |
| 12:38 ET | 851 | 5 |
| 12:48 ET | 100 | 5.06 |
| 12:54 ET | 9472 | 5 |
| 12:56 ET | 2118 | 4.99 |
| 01:10 ET | 500 | 4.99 |
| 01:12 ET | 100 | 5.025 |
| 01:14 ET | 633 | 5.03 |
| 01:15 ET | 423 | 5.03 |
| 01:24 ET | 1218 | 5 |
| 01:33 ET | 100 | 5.025 |
| 01:37 ET | 280 | 5.05 |
| 01:39 ET | 400 | 5.0005 |
| 01:46 ET | 980 | 5 |
| 01:55 ET | 877 | 5.03 |
| 02:42 ET | 100 | 5.07 |
| 02:54 ET | 400 | 5.07 |
| 03:27 ET | 100 | 5.06 |
| 03:41 ET | 100 | 5.06 |
| 03:43 ET | 900 | 5.07 |
| 03:56 ET | 10400 | 5.045 |
| 03:57 ET | 604 | 5.045 |
| 03:59 ET | 12306 | 5 |
Apr 18, 2024
DJ Aileron Therapeutics Is Maintained at Buy by Ladenburg Thalmann, from 8:46AM ET on Thursday Apr 18, 2024 by Dow Jones
8:46AM ET on Thursday Apr 18, 2024 by Dow Jones
Apr 15, 2024
Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update, from 5:20PM ET on Monday Apr 15, 2024 by Dow Jones
5:20PM ET on Monday Apr 15, 2024 by Dow Jones*DJ Aileron Therapeutics 4Q Loss/Shr $1.54 >ALRN, from 5:20PM ET on Monday Apr 15, 2024 by Dow Jones
5:20PM ET on Monday Apr 15, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Aileron Therapeutics Inc | 83.7M | -1.5x | --- |
InflaRx NV | 80.1M | -1.6x | --- |
Tiziana Life Sciences Ltd | 80.8M | -5.6x | --- |
Sellas Life Sciences Group Inc | 86.7M | -1.1x | --- |
PMV Pharmaceuticals Inc | 86.9M | -1.2x | --- |
Chimerix Inc | 80.8M | -1.0x | --- |
Company Information
Aileron Therapeutics, Inc. is a biopharmaceutical company. The Company is advancing a pipeline of medicines to address unmet medical needs in orphan pulmonary and fibrosis indications. Its lead product candidate, LTI-03, is a synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. LTI-03 is being evaluated in a Phase Ib clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). Its second product candidate, LTI-01, is a proenzyme, or zymogen, designed to slowly activate in the pleural space and break up the scar tissue, allowing for drainage of the pleural effusion. It has completed Phase Ib and Phase IIa clinical trials for the treatment of loculated pleural effusions.
Contact Information
- Headquarters
- 12407 N. Mopac Expy., Suite 250 #390AUSTIN, TX, United States 78758
- Phone
- 617-995-0900
- Fax
- 617-995-2410
Executives
- Independent Chairman of the Board
- Josef von Rickenbach
- President, Chief Executive Officer, Director
- Brian Windsor
- Principal Financial Officer
- Charles Garner
- Director
- Manuel Alves Aivado
- Independent Director
- Reinhard Ambros
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $83.7M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 17.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.29 |
EPS | $-3.39 |
Book Value | $20.12 |
P/E Ratio | -1.5x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
